menu
    • menu
    [{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Vernakalant Hydrochloride","moa":"Kir3.1\/Kir3.4 | Voltage-gated potassium channel subunit Kv4.3 | Voltage-gated potassium channel subunit Kv1.5 | Sodium channel protein type V alpha subunit | HERG","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Advanz Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Advanz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Correvio Pharma","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Vernakalant Hydrochloride","moa":"Kir3.1\/Kir3.4 | Voltage-gated potassium channel subunit Kv4.3 | Voltage-gated potassium channel subunit Kv1.5 | Sodium channel protein type V alpha subunit | HERG","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Correvio Pharma","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Correvio Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Correvio Pharma \/ Advanz Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Vernakalant Hydrochloride

    Menu

    Vernakalant Hydrochloride

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Correvio Pharma

                            Canada arrow
                            CTAD25
                            Not Confirmed

                            Correvio Pharma

                            Canada arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vernakalant Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Advanz Pharma

                            Deal Size : $76.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Advanz Pharma Limited Closes Acquisition of Specialty Pharmaceutical Company Correvio Pharma Corp

                            Details : Advanz Pharma believes that Correvio's niche portfolio, consisting of an established brand, and two growing, patent-protected brands, plus a pipeline of potential product launches, are highly complementary to its current priorities and future focus.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $76.0 million

                            May 27, 2020

                            Lead Product(s) : Vernakalant Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Advanz Pharma

                            Deal Size : $76.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Advanz Pharma

                            United Kingdom arrow
                            CTAD25
                            Not Confirmed

                            Advanz Pharma

                            United Kingdom arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vernakalant Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation...

                            Details : Vernakalant HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atrial Fibrillation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 03, 2010

                            Lead Product(s) : Vernakalant Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth